Ad
related to: abbvie bispecific antibody
Search results
Results from the WOW.Com Content Network
Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. [4] [7] Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. [4] [7] Epcoritamab was co-developed by AbbVie and Genmab. [8]
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. [1] Naturally occurring antibodies typically only target one antigen. BsAbs can be manufactured in several structural formats.
[9] [10] It is a bispecific GPRC5D-directed CD3 T-cell engager. [9] Talquetamab is a bispecific antibody against two targets: human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen with potential antineoplastic activity. [11]
AbbVie (NYSE: ABBV) Q4 2024 Earnings Call ... and our BCMA-CD3 bispecific for multiple myeloma 383. ... and advancement of our anti-TREM1 antibody, ABBV-8736 with the eventual goal to add it to ...
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response ...
Seattle Genetics is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer.
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. [2] [3] [5] It bispecifically binds CD20 and CD3 to engage T-cells. [2] [3] It was developed by Genentech. [6] The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache.
sdAb: single-domain antibody; BsAb: bispecific monoclonal antibody: 3funct: trifunctional antibody; BiTE: bi-specific T-cell engager; This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not
Ad
related to: abbvie bispecific antibody